Treatment with SS-31 prevented mitochondrial dysfunction and enhanced ΔΨm, and increased neuroprotective gene PGC-1α in neuroblastoma N2a cells grown with mutant APP (Manczak et al., 2010), suggesting beneficial effects of the drug on mitochondrial alterations in AD. Here, PPARGC1A is linked to Alzheimer disease.